Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Dermata Therapeutics, Inc.

  • SAN DIEGO, California
  • Public · NASDAQ: DRMA
  • 9 employees
$4.7MMarket cap
-$7.6MNet income
9Employees
DRMANASDAQ
2021IPO

About Dermata Therapeutics, Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$7.6M
Total assets
$7.9M
Market cap
$4.7M

Source: SEC EDGAR · updated Jun 8, 2026

NASDAQ: DRMA

15-minute delayed · data by Polygon.io

Market cap
$4.7M
Open
Day range
Prev close
Volume
IPO date
Aug 13, 2021

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review Dermata Therapeutics, Inc..

Write a review
Explore

Similar companies

Browse all →